In August 2025, the stock price of Abivax surged by around 580% following dual Phase III success in ulcerative colitis. Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate. The company is positioned as a potential market leader in inflammatory bowel disease treatment with a novel mechanism of action.
Cyborg Score Rationale
The company's stock surged by around 580% in August 2025 following dual Phase III success in ulcerative colitis. According to 11 analysts, the average rating for ABVX stock is Strong Buy with a 12-month stock price target of $130.09. However, as a clinical-stage company, execution risk remains on commercialization.
Top Insights
Stock surged 580% in August 2025 following dual Phase III success in ulcerative colitis, validating novel miR-124 mechanism
Lead candidate obefazimod in Phase 3 trials for ulcerative colitis and Phase 2b trials for Crohn's disease, two major inflammatory bowel diseases
Market speculation surrounding potential acquisition by Eli Lilly at €15 billion valuation suggests major pharma interest in the platform
2024 revenue grew 136% to $10.79M while losses were $176.24M, indicating pre-commercial stage with R&D-focused burn
Named Competitors
Rinvoq — JAK inhibitor for ulcerative colitis and Crohn's disease
Ozanimod — S1P receptor modulator for ulcerative colitis
Remicade — TNF inhibitor biologic for inflammatory bowel disease
Recent Developments
(August 2025) Dual Phase 3 trial success for obefazimod in ulcerative colitis with 16.4% placebo-adjusted clinical remission rate
(January 2026) Analyst consensus rating of Strong Buy with $130.09 price target
(2025) Continued Phase 2b development in Crohn's disease with preparation for additional inflammatory indications
Open the full interactive Abivax SA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.